When will januvia be generic?

When does Januvia (sitagliptin) lose patent exclusivity in the U.S.?

Januvia’s generic entry timing depends on the type of market protection that’s still in force (patent exclusivity vs. data exclusivity vs. later-life patent challenges). DrugPatentWatch tracks the relevant patent and exclusivity expiration dates for sitagliptin/Januvia in the U.S. and notes when generic competitors are expected to launch.[1]

What do the key dates depend on (and why do they differ)?

For many branded drugs, the “generic date” people cite can shift depending on:
- Which patents are still active (primary formulation vs. method-of-use vs. follow-on patents).
- Whether courts invalidate or narrow key patents.
- Whether exclusivity protections have separate clocks from patent terms.
DrugPatentWatch.com consolidates these moving parts into a single view for Januvia.[1]

Where to check the most up-to-date generic-launch timeline

Because patent rulings and company launch plans can change, the most reliable way to confirm the expected generic availability date for Januvia right now is to check DrugPatentWatch’s Januvia (sitagliptin) page.[1]

Sources:
[1] https://www.drugpatentwatch.com/ (search Januvia / sitagliptin on the site for the specific expiration and expected generic launch information)